Boundless Bio Reports Q2 2025 Financial Results with $15.7 Million Net Loss

Boundless Bio, Inc. reported its financial results for the second quarter of 2025, revealing a net loss of $15.7 million, a slight improvement from the $17.0 million loss recorded in the same period of the previous year. For the six months ending June 30, 2025, the company incurred a net loss of $31.4 million, compared to $32.4 million for the first half of 2024. The decrease in losses is attributed to a reduction in operating expenses, which totaled $17.1 million for the quarter, down from $19.4 million a year earlier. This decline was primarily driven by a decrease in research and development expenses, which fell to $12.2 million from $14.7 million, reflecting reduced spending on clinical trials.

In terms of financial position, Boundless Bio reported total assets of $179.5 million as of June 30, 2025, down from $206.4 million at the end of 2024. The decrease in assets was largely due to a reduction in cash and cash equivalents, which dropped to $14.7 million from $26.6 million. The company’s accumulated deficit increased to $232.9 million, highlighting the ongoing financial challenges as it continues to invest heavily in research and development without generating revenue. The company has not yet commercialized any products and does not expect to do so until it secures regulatory approval for its ecDNA-directed therapeutic candidates.

Strategically, Boundless Bio has made significant changes to its operational focus. On May 23, 2025, the company announced a portfolio prioritization that included a workforce reduction of approximately one-third, aimed at streamlining operations and extending its cash runway into the first half of 2028. The company is now concentrating on advancing its clinical-stage candidates, BBI-355 and BBI-825, and has opened a new combination arm of the POTENTIATE trial for enrollment. Additionally, the company is developing an ecDNA diagnostic test, ECHO, to identify patients who may benefit from its therapies.

Looking ahead, Boundless Bio anticipates continued losses as it progresses through clinical trials and seeks regulatory approvals for its ecDTx. The company has raised a total of $353.8 million since its inception, including $87.7 million from its initial public offering in April 2024. As of June 30, 2025, it had cash, cash equivalents, and short-term investments totaling $127.1 million, which it believes will be sufficient to fund operations into 2028. However, the company acknowledges the need for substantial additional funding to support ongoing research and development activities, and it may pursue equity offerings or other financing arrangements to meet its capital requirements.